A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma

OBJECTIVE: Previous studies reported that 4-1BB-based CD19 chimeric antigen receptor (CAR)-T cells were more beneficial for the clinical outcomes than CD28-based CAR-T cells, especially the lower incidence rate of severe adverse events. However, the median progression-free survival (mPFS) of 4-1BB-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Zhitao, He, Ting, Jin, Shanzhao, Wang, Xiaopei, Zheng, Wen, Lin, Ningjing, Tu, Meifeng, Xie, Yan, Ping, Lingyan, Liu, Weiping, Deng, Lijuan, Ding, Yanping, Hu, Xuelian, Bu, Bing, Lu, Xin’an, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913256/
https://www.ncbi.nlm.nih.gov/pubmed/35355931
http://dx.doi.org/10.21147/j.issn.1000-9604.2022.01.05

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913256/
https://www.ncbi.nlm.nih.gov/pubmed/35355931
http://dx.doi.org/10.21147/j.issn.1000-9604.2022.01.05

Ejemplares similares